These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 38716974)
1. Human Papillomavirus vaccination coverage among the female population living in the state of Goiás, Brazil, 2014-2020: a time series study. Oliveira IM; Martins BCT; Soares LR Epidemiol Serv Saude; 2024; 33():e2023895. PubMed ID: 38716974 [TBL] [Abstract][Full Text] [Related]
2. Vaccination coverage rates and predictors of HPV vaccination among eligible and non-eligible female adolescents at the Brazilian HPV vaccination public program. Faisal-Cury A; Levy RB; Tourinho MF; Grangeiro A; Eluf-Neto J BMC Public Health; 2020 Apr; 20(1):458. PubMed ID: 32252705 [TBL] [Abstract][Full Text] [Related]
3. Social determinants of community-level human papillomavirus vaccination coverage in aschool-based vaccination programme. Jean S; Elshafei M; Buttenheim A Sex Transm Infect; 2018 Jun; 94(4):248-253. PubMed ID: 29330310 [TBL] [Abstract][Full Text] [Related]
4. Vaccination coverage and abandonment among children under two years old in Brazil: a time-series study. Enore RMB; Freitas BHBM; Silva RAD; Gaíva MAM Rev Paul Pediatr; 2024; 42():e2023116. PubMed ID: 38836806 [TBL] [Abstract][Full Text] [Related]
5. Human papillomavirus (HPV) vaccination coverage in Brazil: spatial and age cohort heterogeneity. Moura LL; Codeço CT; Luz PM Rev Bras Epidemiol; 2020; 24():e210001. PubMed ID: 33331411 [TBL] [Abstract][Full Text] [Related]
6. Introduction of a National HPV vaccination program into Bhutan. Dorji T; Tshomo U; Phuntsho S; Tamang TD; Tshokey T; Baussano I; Franceschi S; Clifford G Vaccine; 2015 Jul; 33(31):3726-30. PubMed ID: 26057136 [TBL] [Abstract][Full Text] [Related]
7. Quadrivalent human papillomavirus vaccination successfully reduces the prevalence of vaccine-targeted genotypes in a young, vaccine-eligible-age sample of Australian females. Subasinghe AK; Wark JD; Phillips S; Cornall A; Brotherton JML; Garland SM Sex Health; 2020 Dec; 17(6):510-516. PubMed ID: 33341122 [TBL] [Abstract][Full Text] [Related]
8. Environmental factors associated with human papillomavirus vaccine coverage in adolescents: 2016-2020 analysis. Luvisaro BMO; Silva TPRD; Silva TMRD; Lachtim SAF; Souza JFA; Matozinhos FP Rev Lat Am Enfermagem; 2022; 30(spe):e3804. PubMed ID: 36449925 [TBL] [Abstract][Full Text] [Related]
9. Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study. Sankaranarayanan R; Joshi S; Muwonge R; Esmy PO; Basu P; Prabhu P; Bhatla N; Nene BM; Shaw J; Poli URR; Verma Y; Zomawia E; Pimple S; Tommasino M; Pawlita M; Gheit T; Waterboer T; Sehr P; Pillai MR; Vaccine; 2018 Aug; 36(32 Pt A):4783-4791. PubMed ID: 29551226 [TBL] [Abstract][Full Text] [Related]
10. Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study. Chow EPF; Machalek DA; Tabrizi SN; Danielewski JA; Fehler G; Bradshaw CS; Garland SM; Chen MY; Fairley CK Lancet Infect Dis; 2017 Jan; 17(1):68-77. PubMed ID: 27282422 [TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of the introduction of two-dose bi-valent (Cervarix) and quadrivalent (Gardasil) HPV vaccination for adolescent girls in Bangladesh. Mahumud RA; Gow J; Alam K; Keramat SA; Hossain MG; Sultana M; Sarker AR; Islam SMS Vaccine; 2020 Jan; 38(2):165-172. PubMed ID: 31668820 [TBL] [Abstract][Full Text] [Related]
12. Human papillomavirus vaccine coverage in Rwanda: A population-level analysis by birth cohort. Sayinzoga F; Umulisa MC; Sibomana H; Tenet V; Baussano I; Clifford GM Vaccine; 2020 May; 38(24):4001-4005. PubMed ID: 32336599 [TBL] [Abstract][Full Text] [Related]
13. Human papillomavirus vaccination coverage in Northeast Brazil, 2013-2021: a descriptive study. Glehn MPV; Nascimento LMD; Freire KMR; Minuzzi TTCES; Hott CE; Maranhão AGK; Moraes C Epidemiol Serv Saude; 2023; 32(2):e2022790. PubMed ID: 37222355 [TBL] [Abstract][Full Text] [Related]
14. Adverse events following Quadrivalent HPV vaccination reported in Sao Paulo State, Brazil, in the first three years after introducing the vaccine for routine immunization (March 2014 to December 2016). Mauro AB; Fernandes EG; Miyaji KT; Arantes BA; Valente MG; Sato HK; Sartori AMC Rev Inst Med Trop Sao Paulo; 2019 Sep; 61():e43. PubMed ID: 31531621 [TBL] [Abstract][Full Text] [Related]
15. Age impact on human papillomavirus vaccination in France in 2014: A study from the National Health Insurance Database. Héquet D; Pouget N; Estevez JP; Robain M; Rouzier R Bull Cancer; 2015 Nov; 102(11):892-7. PubMed ID: 26526386 [TBL] [Abstract][Full Text] [Related]
16. Human papillomavirus vaccination coverage in Luxembourg - Implications of lowering and restricting target age groups. Latsuzbaia A; Arbyn M; Weyers S; Mossong J Vaccine; 2018 Apr; 36(18):2411-2416. PubMed ID: 29602702 [TBL] [Abstract][Full Text] [Related]
17. Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study. Basu P; Malvi SG; Joshi S; Bhatla N; Muwonge R; Lucas E; Verma Y; Esmy PO; Poli URR; Shah A; Zomawia E; Pimple S; Jayant K; Hingmire S; Chiwate A; Divate U; Vashist S; Mishra G; Jadhav R; Siddiqi M; Sankaran S; Prabhu PR; Kannan TPRA; Varghese R; Shastri SS; Anantharaman D; Gheit T; Tommasino M; Sauvaget C; Pillai MR; Sankaranarayanan R Lancet Oncol; 2021 Nov; 22(11):1518-1529. PubMed ID: 34634254 [TBL] [Abstract][Full Text] [Related]